Drugs / ARCT-2303
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06279871 | Mar → Oct 2024 | COVID-19 | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARCT-2303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06279871 ↗ |
| Route | Intramuscular | “Participants will receive one 0.5-mL IM (intramuscular) dose of ARCT-2303” NCT06279871 ↗ |